ClinicalTrials.gg
CompletedNCT04379713Updated Jun 13, 2023Results posted

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 97 sites in 11 countries. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-13.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,511
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
4th of 19
1,511 · median 668
Started
2020
with 4 others
Phase 3
14 of 19
1 open now
Registered
4th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 4th largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 4th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 98 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female infants born at ≥34 weeks of gestation and who are 2 months of age (≥42 to ≤98 days) at the time of consent (the day of birth is considered day of life 1).
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any licensed or pneumococcal vaccine, or planned receipt through study participation.
  • Major known congenital malformation or serious chronic disorder.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,511 participants (actual)

Study arms

  • Experimental
    20-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine

    Biological: 20-valent pneumococcal conjugate vaccine

  • Active comparator
    13-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Dose 1

    Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: greater than (\>) 0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.

    Time frame: Within 7 Days after Dose 1

  2. Percentage of Participants With Local Reactions Within 7 Days After Dose 2

    Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.

    Time frame: Within 7 Days after Dose 2

  3. Percentage of Participants With Local Reactions Within 7 Days After Dose 3

    Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.

    Time frame: Within 7 Days after Dose 3

  4. Percentage of Participants With Local Reactions Within 7 Days After Dose 4

    Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.

    Time frame: Within 7 Days after Dose 4

  5. Percentage of Participants With Systemic Events Within 7 Days After Dose 1

    Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature greater than or equal to (\>=) 38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

    Time frame: Within 7 Days after Dose 1

  6. Percentage of Participants With Systemic Events Within 7 Days After Dose 2

    Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

    Time frame: Within 7 Days after Dose 2

  7. Percentage of Participants With Systemic Events Within 7 Days After Dose 3

    Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

    Time frame: Within 7 Days after Dose 3

  8. Percentage of Participants With Systemic Events Within 7 Days After Dose 4

    Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

    Time frame: Within 7 Days after Dose 4

  9. Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Dose 1 to 1 Month after Dose 3

  10. Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Dose 4 to 1 Month after Dose 4

  11. Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 4

    A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect and other important medical events.

    Time frame: From Dose 1 to 6 Months after Dose 4

  12. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 4

    An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects.

    Time frame: From Dose 1 to 6 Months after Dose 4

07

Results

Posted Jun 13, 2023

Participant flow

Participant flow — Overall Study
Milestone20vPnC13vPnC
Started1006505
Dose 11000504
Dose 2972492
Dose 3964483
Dose 4923462
Completed910451
Not completed9654
Withdrew: Adverse event20
Withdrew: Physician decision21
Withdrew: Protocol violation116
Withdrew: No longer met eligibility criteria1411
Withdrew: Withdrawal by parent/guardian3615
Withdrew: Lost to follow-up3121

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1

Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: greater than (\>) 0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1
Percentage of participants20vPnC13vPnC
Redness: Mild18.0 ± 15.716.5 ± 13.3
Redness: Moderate3.7 ± 2.63.0 ± 1.7
Redness: Severe0 ± 0.00 ± 0.0
Swelling: Mild13.8 ± 11.711.2 ± 8.6
Swelling: Moderate6.1 ± 4.75.4 ± 3.6
Swelling: Severe0 ± 0.00 ± 0.0
Pain at injection site: Mild24.8 ± 22.125.3 ± 21.5
Pain at injection site: Moderate15.5 ± 13.316.7 ± 13.5
Pain at injection site: Severe0.2 ± 0.00 ± 0.0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2

Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.

Time frame:
Within 7 Days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2
Percentage of participants20vPnC13vPnC
Redness: Mild20.4 ± 17.919.4 ± 16.0
Redness: Moderate3.2 ± 2.13.9 ± 2.4
Redness: Severe0 ± 0.00 ± 0.0
Swelling: Mild13.4 ± 11.313.4 ± 10.5
Swelling: Moderate4.4 ± 3.25.6 ± 3.7
Swelling: Severe0 ± 0.00 ± 0.0
Pain at the injection site: Mild20.8 ± 18.320.2 ± 16.7
Pain at the injection site: Moderate10.7 ± 8.811.8 ± 9.0
Pain at the injection site: Severe0.7 ± 0.30.8 ± 0.2
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 3

Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.

Time frame:
Within 7 Days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Percentage of participants20vPnC13vPnC
Redness: Mild19.4 ± 16.917.0 ± 13.7
Redness: Moderate3.8 ± 2.73.1 ± 1.8
Redness: Severe0 ± 0.00.2 ± 0.0
Swelling: Mild12.2 ± 10.213.0 ± 10.1
Swelling: Moderate4.1 ± 3.03.1 ± 1.8
Swelling: Severe0 ± 0.00.2 ± 0.0
Pain at the injection site: Mild16.3 ± 14.016.6 ± 13.3
Pain at the injection site: Moderate8.3 ± 6.610.3 ± 7.7
Pain at the injection site: Severe0.1 ± 0.00 ± 0.0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 4

Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.

Time frame:
Within 7 Days after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 4
Percentage of participants20vPnC13vPnC
Redness: Mild15.1 ± 12.819.4 ± 15.8
Redness: Moderate5.9 ± 4.52.4 ± 1.2
Redness: Severe0.1 ± 0.00 ± 0.0
Swelling: Mild10.1 ± 8.211.5 ± 8.7
Swelling: Moderate4.7 ± 3.42.9 ± 1.5
Swelling: Severe0 ± 0.00 ± 0.0
Pain at the injection site: Mild19.8 ± 17.321.8 ± 18.1
Pain at the injection site: Moderate10.2 ± 8.310.1 ± 7.5
Pain at the injection site: Severe0.8 ± 0.30 ± 0.0
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1

Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature greater than or equal to (\>=) 38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Percentage of participants20vPnC13vPnC
Fever: >=38.0 degrees C to 38.4 degrees C6.3 (4.8 to 7.9)7.8 (5.6 to 10.6)
Fever: >38.4 degrees C to 38.9 degrees C2.3 (1.5 to 3.5)1.8 (0.8 to 3.4)
Fever: >38.9 degrees C to 40.0 degrees C0.7 (0.3 to 1.4)0.2 (0.0 to 1.1)
Fever: >40.0 degrees C0 (0.0 to 0.4)0 (0.0 to 0.7)
Decreased appetite: Mild14.2 (12.1 to 16.5)14.7 (11.7 to 18.1)
Decreased appetite: Moderate10.3 (8.5 to 12.3)8.6 (6.3 to 11.5)
Decreased appetite: Severe0.5 (0.2 to 1.2)0.4 (0.0 to 1.4)
Drowsiness: Mild48.5 (45.3 to 51.6)47.4 (42.9 to 51.9)
Drowsiness: Moderate15.8 (13.6 to 18.2)14.5 (11.5 to 17.9)
Drowsiness: Severe0.5 (0.2 to 1.2)0.4 (0.0 to 1.4)
Irritability: Mild22.7 (20.1 to 25.4)22.9 (19.3 to 26.8)
Irritability: Moderate41.2 (38.1 to 44.4)41.4 (37.0 to 45.8)
Irritability: Severe4.3 (3.2 to 5.8)4.2 (2.6 to 6.4)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2

Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

Time frame:
Within 7 Days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Percentage of participants20vPnC13vPnC
Fever: >=38.0 degrees C to 38.4 degrees C10.6 (8.7 to 12.7)8.5 (6.1 to 11.3)
Fever: >38.4 degrees C to 38.9 degrees C3.6 (2.5 to 5.0)2.7 (1.4 to 4.5)
Fever: >38.9 degrees C to 40.0 degrees C1.4 (0.7 to 2.3)0.2 (0.0 to 1.1)
Fever: >40.0 degrees C0 (0.0 to 0.4)0 (0.0 to 0.8)
Decreased appetite: Mild13.4 (11.3 to 15.8)12.0 (9.2 to 15.2)
Decreased appetite: Moderate9.6 (7.8 to 11.6)8.2 (6.0 to 11.1)
Decreased appetite: Severe0.7 (0.3 to 1.5)0.4 (0.0 to 1.5)
Drowsiness: Mild35.3 (32.3 to 38.4)35.3 (31.0 to 39.7)
Drowsiness: Moderate13.4 (11.3 to 15.8)13.8 (10.9 to 17.2)
Drowsiness: Severe0.4 (0.1 to 1.1)1.2 (0.5 to 2.7)
Irritability: Mild23.2 (20.6 to 26.0)19.8 (16.3 to 23.6)
Irritability: Moderate37.3 (34.2 to 40.4)42.7 (38.2 to 47.2)
Irritability: Severe4.2 (3.0 to 5.7)5.2 (3.4 to 7.5)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 3

Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

Time frame:
Within 7 Days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Percentage of participants20vPnC13vPnC
Fever: >=38.0 degrees C to 38.4 degrees C7.4 (5.9 to 9.3)8.2 (5.9 to 11.0)
Fever: >38.4 degrees C to 38.9 degrees C2.9 (1.9 to 4.2)0.6 (0.1 to 1.8)
Fever: >38.9 degrees C to 40.0 degrees C1.3 (0.7 to 2.2)1.0 (0.3 to 2.4)
Fever: >40.0 degrees C0 (0.0 to 0.4)0 (0.0 to 0.8)
Decreased appetite: Mild15.0 (12.8 to 17.4)10.5 (7.9 to 13.6)
Decreased appetite: Moderate8.2 (6.5 to 10.1)6.3 (4.3 to 8.9)
Decreased appetite: Severe0.4 (0.1 to 1.1)0.4 (0.1 to 1.5)
Drowsiness: Mild26.6 (23.8 to 29.5)27.3 (23.3 to 31.5)
Drowsiness: Moderate8.5 (6.8 to 10.5)9.0 (6.6 to 12.0)
Drowsiness: Severe0.2 (0.0 to 0.8)0 (0.0 to 0.8)
Irritability: Mild22.3 (19.7 to 25.1)22.2 (18.6 to 26.2)
Irritability: Moderate30.1 (27.2 to 33.2)29.8 (25.7 to 34.1)
Irritability: Severe2.3 (1.5 to 3.5)2.7 (1.5 to 4.6)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 4

Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

Time frame:
Within 7 Days after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 4
Percentage of participants20vPnC13vPnC
Fever: >=38.0 degrees C to 38.4 degrees C9.8 (7.9 to 11.9)9.5 (6.9 to 12.5)
Fever: >38.4 degrees C to 38.9 degrees C4.5 (3.2 to 6.1)4.2 (2.5 to 6.5)
Fever: >38.9 degrees C to 40.0 degrees C3.7 (2.6 to 5.2)3.1 (1.7 to 5.1)
Fever: >40.0 degrees C0.1 (0.0 to 0.6)0.2 (0.0 to 1.2)
Decreased appetite: Mild16.1 (13.8 to 18.7)12.3 (9.5 to 15.7)
Decreased appetite: Moderate10.5 (8.6 to 12.7)11.7 (8.9 to 15.0)
Decreased appetite: Severe1.7 (0.9 to 2.8)1.8 (0.8 to 3.4)
Drowsiness: Mild24.2 (21.4 to 27.2)25.1 (21.2 to 29.4)
Drowsiness: Moderate12.2 (10.1 to 14.6)10.6 (7.9 to 13.8)
Drowsiness: Severe0.7 (0.2 to 1.5)0.2 (0.0 to 1.2)
Irritability: Mild21.4 (18.8 to 24.3)22.0 (18.3 to 26.1)
Irritability: Moderate31.4 (28.4 to 34.5)29.7 (25.6 to 34.2)
Irritability: Severe2.5 (1.6 to 3.7)3.3 (1.9 to 5.4)
PrimaryPercentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Dose 1 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3
Percentage of participants20vPnC13vPnC
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 329.6 ± 26.827.6 ± 23.8
PrimaryPercentage of Participants With AEs From Dose 4 to 1 Month After Dose 4

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Dose 4 to 1 Month after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4
Percentage of participants20vPnC13vPnC
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 415.1 ± 12.815.8 ± 12.6
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 4

A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect and other important medical events.

Time frame:
From Dose 1 to 6 Months after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 4
Percentage of participants20vPnC13vPnC
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 44.4 ± 3.25.6 ± 3.7
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 4

An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects.

Time frame:
From Dose 1 to 6 Months after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 4
Percentage of participants20vPnC13vPnC
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 42.8 ± 1.92.8 ± 1.5

Adverse events

Collected over Local reactions and systemic events recorded using systematic assessment: within 7 days after Dose 1, 2, 3, 4; SAEs and all-cause mortality recorded using non-systematic assessment: From Dose 1 up to 6 months after Dose 4; other AEs recorded using non-systematic assessment: from Dose 1 up to 1 month after Dose 3 and from Dose 4 up to 1 month after Dose 4. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20vPnC0/1,000 (0%)44/1,000 (4.4%)960/1,000 (96%)
13vPnC0/503 (0%)28/503 (5.6%)481/503 (95.6%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
Event20vPnC13vPnC
BronchiolitisInfections and infestations5/10005/503
PyrexiaGeneral disorders1/10003/503
GastroenteritisInfections and infestations3/10002/503
Otitis media acuteInfections and infestations1/10002/503
Urinary tract infectionInfections and infestations1/10002/503
Adenovirus infectionInfections and infestations2/10000/503
PneumoniaInfections and infestations2/10000/503
Respiratory syncytial virus infectionInfections and infestations2/10000/503
AnaemiaBlood and lymphatic system disorders0/10001/503
Allergic colitisGastrointestinal disorders0/10001/503
Most frequent other events
Most frequent other events
Event20vPnC13vPnC
Irritability (IRRITABILITY)Psychiatric disorders883/1000432/503
Hypersomnia (INCREASED SLEEP)Nervous system disorders809/1000389/503
Injection site pain (PAIN)General disorders609/1000309/503
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders549/1000249/503
Injection site erythema (REDNESS)General disorders455/1000224/503
Injection site swelling (SWELLING)General disorders372/1000176/503
Pyrexia (FEVER)General disorders336/1000159/503
Upper respiratory tract infectionInfections and infestations59/100028/503

Baseline characteristics

Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received any incorrect study vaccination during the study was excluded.

Age, Continuous
Age, Continuous(Days)20vPnC13vPnCTotal
Mean64.6 ± 8.5165.0 ± 8.9564.8 ± 8.66
Sex: Female, Male
Sex: Female, Male(Participants)20vPnC13vPnCTotal
Female483259742
Male517244761
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20vPnC13vPnCTotal
Hispanic or Latino367193560
Not Hispanic or Latino621303924
Unknown or Not Reported12719
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20vPnC13vPnCTotal
American Indian or Alaska Native415
Asian211031
Native Hawaiian or Other Pacific Islander224
Black or African American551570
White8684451313
More than one race352156
Unknown or Not Reported15924
08

Study locations

97 sites
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • Good Samaritan Family Health Team
    Fullerton, California 92831, United States
  • FocilMed
    Oxnard, California 93030, United States
  • Superior Research, LLC
    Sacramento, California 95831, United States
  • Carey Chronis, MD
    Ventura, California 93003, United States
  • Fomat - Robert Nudelman MD
    Westlake Village, California 91361, United States
  • Ebert Family Clinic
    Frisco, Colorado 80443, United States
  • Advanced Research for Health Improvement, LLC
    Fort Myers, Florida 33907, United States
  • Pensacola Pediatrics
    Gulf Breeze, Florida 32563, United States
  • Y&L Advance Health Care Inc, d/b/a Elite
    Miami, Florida 33144, United States
  • Advanced Research for Health Improvement, LLC
    Naples, Florida 34102, United States
  • Citadelle Clinical Research
    North Miami Beach, Florida 33162, United States
  • Avanza Medical Research Center
    Pensacola, Florida 32503, United States
  • Pensacola Pediatrics
    Pensacola, Florida 32504, United States
  • KIDZ Medical Services Pediatric Pulmonary Center
    South Miami, Florida 33143, United States
  • Teena Hughes/PAS Research
    Tampa, Florida 33613, United States
  • Idaho Falls Pediatrics
    Ammon, Idaho 83406, United States
  • Elite Clinical Trials LLLP
    Blackfoot, Idaho 83221, United States
  • Idaho Falls Pediatrics
    Idaho Falls, Idaho 83402, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • The Pediatric Center
    Idaho Falls, Idaho 83404, United States
  • Cotton O'Neil Clinical Research Center, Pediatrics
    Topeka, Kansas 66604, United States
  • All Children Pediatrics
    Louisville, Kentucky 40243, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • MedClinical Research Partners, LLC
    East Orange, New Jersey 07018, United States
  • Advantage Clinical Trials
    Bronx, New York 10468, United States
  • Pediatric Partners, PA
    Raleigh, North Carolina 27609, United States
  • PMG Research Inc., d/b/a PMG Research of Piedmont HealthCare
    Statesville, North Carolina 28625, United States
  • Ford Simpson Lively and Rice Pedtrics, PA (Wake Health Network)
    Winston-Salem, North Carolina 27103, United States
  • PMG Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Coastal Pediatric Research
    Summerville, South Carolina 29486, United States
  • The Jackson Clinic, PA
    Jackson, Tennessee 38305, United States
  • Advent Health Family Medicine Rural Health Clinics, Inc.
    Lampasas, Texas 76550, United States
  • FMC Science
    Lampasas, Texas 76550, United States
  • Maximos Ob/Gyn
    League City, Texas 77573, United States
  • Rio Grande Valley Clinical Research Institute
    Pharr, Texas 78577, United States
  • Tanner Clinic
    Layton, Utah 84041, United States
  • Wasatch Pediatrics - St. Marks Office
    Salt Lake City, Utah 84124, United States
  • CopperView Medical Center
    South Jordan, Utah 84095, United States
  • PI-Coor Clinical Research LLC
    Burke, Virginia 22015, United States
  • Clinica Mayo UMCB S.R.L.
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Hospital del Nino Jesus
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Centro Medico Dra. De Salvo
    Buenos Aires, C1426ABP, Argentina
  • Aggarwal and Associates Limited
    Brampton, Ontario L6T 0G1, Canada
  • Dawson Clinical Research Inc.
    Guelph, Ontario N1H 1B1, Canada
  • Milestone Research , Inc
    London, Ontario N5W 6A2, Canada
  • Bluewater Clinical Research Group Inc.
    Sarnia, Ontario N7T 4X3, Canada
  • Dr. Hartley Garfield Medicine Professional Corporation
    Toronto, Ontario M5G 1N8, Canada
  • Centre hospitalier universitaire (CHU) Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
  • McGill University Health Centre, Vaccine Study Centre
    Pierrefonds, Quebec H9H 4Y6, Canada
  • CHU de Quebec-Universite Laval
    Québec City, Quebec G1E 7G9, Canada
  • CESFAM Colina
    Colina, Santiago, Región Metropolitana 9350079, Chile
  • CESFAM Esmeralda
    Colina, Santiago, Región Metropolitana, Chile
  • Biocinetic
    Santiago, Región Metropolitana 8331143, Chile
  • Grupo Estudios Clínicos Infectología Respiratoria
    Santiago, Región Metropolitana 8380453, Chile
  • Hospital Padre Hurtado
    Santiago, Región Metropolitana 8880465, Chile
  • Ordinace praktickeho lekare pro deti a dorost
    Hradec Kralove, 50004, Czechia
  • Ordinace praktickeho lekare pro deti a dorost
    Jindrichuv Hradec II, 377 01, Czechia
  • Detska ambulance Petriny spol. s r.o.
    Veleslavin, 162 00, Czechia
  • MeVac - Meilahti Vaccine Research Center
    Helsinki, 00290, Finland
  • SIBAmed GmbH & Co.KG
    Leipzig, Saxony 04103, Germany
  • Kinderarztpraxis Bramsche
    Bramsche, 49565, Germany
  • Arztpraxis Dr. med. Dr. rer. nat. Helmut Pabel
    Herford, 32049, Germany
  • Praxis fuer Kinderpneumologie und Allergologie Mannheim
    Mannheim, 68161, Germany
  • Kinderarztpraxis Ralph Köllges, Jacek Mossakowski, Dr. med. Martina Meyer-Krott
    Mönchengladbach, 41236, Germany
  • Praxis Dr. med. Joachim Weimer
    Reinfeld, 23858, Germany
  • University General Hospital of Heraklion
    Heraklion, Crete 71110, Greece
  • General University Hospital of Larissa
    Larissa, Thessaly 41110, Greece
  • "Aghia Sophia" Children's Hospital
    Athens, 11527, Greece
  • P. and A. Kyriakou Children's Hospital
    Athens, 11527, Greece
  • University General Hospital "ATTIKON"
    Athens, 12462, Greece
  • "Ippokratio" General Hospital of Thessaloniki
    Thessaloniki, 54642, Greece
  • Papp és Tsa Eü és Szolg Bt
    Szigetvar, Baranya 7900, Hungary
  • Dr Pölöskey Péter Egyéni Cég Házi Gyermekorvosi Szolgálat Szombathely
    Szombathely, VAS Megye 9700, Hungary
  • Gyerkőc Med Bt. Házi Gyermekorvosi Rendelő
    Budapest, 1042, Hungary
  • Futurenest Kft. Pestszentimrei Gyermekrendelő
    Budapest, 1188, Hungary
  • Gyorine dr Bari Eszter E. V. 1. sz. Gyermek Haziorvosi Praxis
    Csongrad, 6640, Hungary
  • Futurenest Kft. 16. házi gyermekorvosi rendelő
    Debrecen, 4025, Hungary
  • Mimiped Bt
    Gyor, 9024, Hungary
  • Futurenest Kft
    Miskolc, 3527, Hungary
  • Bettimedical BT
    Szazhalombatta, 2440, Hungary
  • Ponce Medical School Foundation Inc./ CAIMED Center
    Ponce, 00176, Puerto Rico
  • CHUS - Hospital Clinico Universitario
    Santiago de Compostela, A Coruna 15706, Spain
  • Hospital Universitari General de Catalunya
    Sant Cugat del Valles, Barcelona 08195, Spain
  • Centro de Salud de Burriana II
    Burriana, Castellon 12530, Spain
  • Hospital Universitario de Burgos
    Burgos, Castilla Y LEON 09006, Spain
  • Hospital Universitario HM Monteprincipe
    Boadilla del Monte, Madrid 28660, Spain
  • Centro de Salud L'Eliana
    L'Eliana, Valencia 46183, Spain
  • Centro de Salud de Paiporta
    Paiporta, Valencia 46200, Spain
  • Clinica Corachan
    Barcelona, 08017, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Grupo Pediatrico Uncibay
    Malaga, 29015, Spain
  • Centro de Salud de Malvarrosa
    Valencia, 46011, Spain
  • FISABIO
    Valencia, 46020, Spain
  • Centro de Salud la Serreria II
    Valencia, 46022, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Aug 2022, 27 months.

Results were first posted in Jun 2023, 9 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 27 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 7, 2020
StartActual
May 21, 2020
Primary completionActual
Aug 31, 2022
CompletionActual
Aug 31, 2022
Results first posted
Jun 13, 2023
Last update
Jun 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04379713
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 7, 2020
Start date
May 21, 2020
Primary completion
Aug 31, 2022
Completion
Aug 31, 2022
Results posted
Jun 13, 2023
Last update
Jun 13, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion